2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Jonathan Douxfils; Dorothy Adcock; Shannon M Bates; Emmanuel J Favaloro; Isabelle Gouin-Thibault; Cecilia Guillermo; Yohko Kawai; Prof Dr Edelgard Lindhoff-Last; Steve Kitchen; Robert Charles Gosselin

doi:10.1055/a-1450-8178

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Jonathan Douxfils, Dorothy Adcock, Shannon M Bates, Emmanuel J Favaloro, Isabelle Gouin-Thibault, Cecilia Guillermo, Yohko Kawai, Prof Dr Edelgard Lindhoff-Last, Steve Kitchen, Robert Charles Gosselin

Research output: Contribution to journal › Article › peer-review

65 Downloads (Pure)

Abstract

In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.

Original language	English
Pages (from-to)	1008-1020
Number of pages	13
Journal	Thrombosis and Haemostasis
Volume	121
Issue number	8
Early online date	19 Mar 2021
DOIs	https://doi.org/10.1055/a-1450-8178
Publication status	Published - 1 Aug 2021

Keywords

diagnosis management
direct oral anticoagulants
guidance
laboratory

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/a-1450-8178

Douxfils-2021--update-of-the-international-cou

Cite this

Douxfils, J., Adcock, D., Bates, S. M., Favaloro, E. J., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, P. D. E., Kitchen, S., & Gosselin, R. C. (2021). 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and Haemostasis, 121(8), 1008-1020. https://doi.org/10.1055/a-1450-8178

@article{1a951a85d0984177b83cb0a7cfbe386b,

title = "2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants",

abstract = "In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.",

keywords = "diagnosis management, direct oral anticoagulants, guidance, laboratory",

author = "Jonathan Douxfils and Dorothy Adcock and Bates, {Shannon M} and Favaloro, {Emmanuel J} and Isabelle Gouin-Thibault and Cecilia Guillermo and Yohko Kawai and Lindhoff-Last, {Prof Dr Edelgard} and Steve Kitchen and Gosselin, {Robert Charles}",

year = "2021",

month = aug,

day = "1",

doi = "10.1055/a-1450-8178",

language = "English",

volume = "121",

pages = "1008--1020",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Schattauer GmbH",

number = "8",

}

Douxfils, J, Adcock, D, Bates, SM, Favaloro, EJ, Gouin-Thibault, I, Guillermo, C, Kawai, Y, Lindhoff-Last, PDE, Kitchen, S & Gosselin, RC 2021, '2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants', Thrombosis and Haemostasis, vol. 121, no. 8, pp. 1008-1020. https://doi.org/10.1055/a-1450-8178

TY - JOUR

T1 - 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

AU - Douxfils, Jonathan

AU - Adcock, Dorothy

AU - Bates, Shannon M

AU - Favaloro, Emmanuel J

AU - Gouin-Thibault, Isabelle

AU - Guillermo, Cecilia

AU - Kawai, Yohko

AU - Lindhoff-Last, Prof Dr Edelgard

AU - Kitchen, Steve

AU - Gosselin, Robert Charles

PY - 2021/8/1

Y1 - 2021/8/1

N2 - In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.

AB - In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.

KW - diagnosis management

KW - direct oral anticoagulants

KW - guidance

KW - laboratory

UR - http://www.scopus.com/inward/record.url?scp=85107469451&partnerID=8YFLogxK

U2 - 10.1055/a-1450-8178

DO - 10.1055/a-1450-8178

M3 - Article

C2 - 33742436

SN - 0340-6245

VL - 121

SP - 1008

EP - 1020

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 8

ER -

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

The BIOCOAG project : Biological assessment of the control of anticoagulation

Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.

Cite this

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

The BIOCOAG project : Biological assessment of the control of anticoagulation

Student theses

Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.

Cite this